Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Mattes, W B ^a   Kamp, H G ^b   Fabian, E ^b   Herold, M ^c   Krennrich, G ^b   Looser, R ^c   Mellert, W ^b   Prokoudine, A ^c   Strauss, V ^b   Van Ravenzwaay, B ^b   Walk, T ^c   Naraoka, H ^d   Omura, K ^d   Schuppe Koistinen, I ^e   Nadanaciva, S ^f   Bush, E D ^g   Moeller, N ^h   Ruiz Noppinger, P ^h   Piccoli, S P ⁱ  

^a PharmPoint Consulting   (United States)

^b BASF SE   (Germany)

^c Metanomics GmbH   (Germany)

^d ASTELLAS PHARMA INC   (Japan)

^e ASTRAZENECA R AND D   (Sweden)

^f PFIZER INC   (United States)

^g Drug Safety Executive Council   (United States)

^h Metanomics Health GmbH   (Germany)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CAPTOPRIL; CHOLESTEROL; CREATININE; CYCLOSPORIN A; DOXORUBICIN; GLOBULIN; GLUCOSE; HEMOGLOBIN; LISINOPRIL; PHENYTOIN; PHOSPHATE; PROTEIN; CYCLOSPORIN;

ANEMIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENZYME INDUCTION; ERYTHROCYTE COUNT; FEMALE; FOOD INTAKE; HEMATOCRIT; IMMUNE DEFICIENCY; INTRAHEPATIC CHOLESTASIS; KIDNEY TUBULE NECROSIS; LEUKOCYTE COUNT; LIVER TOXICITY; LOW DRUG DOSE; MALE; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; PREDICTION; RAT; RISK ASSESSMENT; SEIZURE; SEX DIFFERENCE; THROMBOCYTE COUNT; WEIGHT GAIN; WEIGHT REDUCTION; ADVERSE DRUG REACTION; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; HUMAN; KIDNEY DISEASE; METABOLISM; METABOLOME; METHODOLOGY; WISTAR RAT; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PROCEDURES;

ANIMALIA; RATTUS;

ANIMALS; CAPTOPRIL; CYCLOSPORINE; DOXORUBICIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; KIDNEY DISEASES; LISINOPRIL; MALE; METABOLOME; METABOLOMICS; PHENYTOIN; RATS; RATS, WISTAR;

EID: 84878694316     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/202497     Document Type: Article

References (74)

1. Brumfitt W., Hamilton-Miller J. M. T., The changing face of chemotherapy. Postgraduate Medical Journal 1988 64 753 552 558 2-s2.0-0023740089
2. Borchers A. T., Hagie F., Keen C. L., Gershwin M. E., The history and contemporary challenges of the US food and drug administration. Clinical Therapeutics 2007 29 1 1 16 2-s2.0-33947188198 10.1016/j.clinthera.2007.01.006 (Pubitemid 46414028)
3. Stevens J. L., Future of toxicology-mechanisms of toxicity and drug safety: where do we go from here? Chemical Research in Toxicology 2006 19 11 1393 1401 2-s2.0-33845340506 10.1021/tx060213n (Pubitemid 44867987)
4. Kola I., Landis J., Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 2004 3 8 711 715 2-s2.0-4344645978 (Pubitemid 39173511)
5. Schmid E. F., Smith D. A., Ryder S. W., Communicating the risks and benefits of medicines. Drug Discovery Today 2007 12 9-10 355 364 2-s2.0-34247339345 10.1016/j.drudis.2007.03.003 (Pubitemid 46636373)
6. Loghman-Adham M., Kiu Weber C. I., Ciorciaro C., Mann J., Meier M., Detection and management of nephrotoxicity during drug development. Expert Opinion on Drug Safety 2012 11 4 581 596 10.1517/14740338.2012.691964
7. Dieterle F., Perentes E., Cordier A., Roth D. R., Verdes P., Grenet O., Pantano S., Moulin P., Wahl D., Mahl A., End P., Staedtler F., Legay F., Carl K., Laurie D., Chibout S. D., Vonderscher J., Maurer G., Urinary clusterin, cystatin C, Β 2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nature Biotechnology 2010 28 5 463 469 2-s2.0-77952164644 10.1038/nbt.1622
8. Gautier J. C., Riefke B., Walter J., Kurth P., Mylecraine L., Guilpin V., Barlow N., Gury T., Hoffman D., Ennulat D., Schuster K., Harpur E., Pettit S., Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with cisplatin. Toxicologic Pathology 2010 38 6 943 956 2-s2.0-78649960507 10.1177/0192623310379139
9. Muller P. Y., Dieterle F., Tissue-specific, non-invasive toxicity biomakers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opinion on Drug Metabolism and Toxicology 2009 5 9 1023 1038 2-s2.0-70249111877 10.1517/17425250903114174
10. Dieterle F., Marrer E., Suzuki E., Grenet O., Cordier A., Vonderscher J., Monitoring kidney safety in drug development: emerging technologies and their implications. Current Opinion in Drug Discovery and Development 2008 11 1 60 71 2-s2.0-37849031048
11. Bugrim A., Nikolskaya T., Nikolsky Y., Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discovery Today 2004 9 3 127 135 2-s2.0-1042302103 10.1016/S1359-6446(03)02971-4 (Pubitemid 38198311)
12. Robertson D. G., Metabonomics in toxicology: a review. Toxicological Sciences 2005 85 2 809 822 2-s2.0-20544466649 10.1093/toxsci/kfi102 (Pubitemid 40846857)
13. van Ravenzwaay B., Cunha G. C. P., Leibold E., Looser R., Mellert W., Prokoudine A., Walk T., Wiemer J., The use of metabolomics for the discovery of new biomarkers of effect. Toxicology Letters 2007 172 1-2 21 28 2-s2.0-34547460023 10.1016/j.toxlet.2007.05.021 (Pubitemid 47161053)
14. Wishart D. S., Applications of metabolomics in drug discovery and development. Drugs in R and D 2008 9 5 307 322 2-s2.0-50149086997 10.2165/00126839-200809050-00002
15. Boudonck K. J., Mitchell M. W., Német L., Keresztes L., Nyska A., Shinar D., Rosenstock M., Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicologic Pathology 2009 37 3 280 292 2-s2.0-67049173139 10.1177/0192623309332992
16. Beger R. D., Sun J., Schnackenberg L. K., Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicology and Applied Pharmacology 2010 243 2 154 166 2-s2.0-77949417518 10.1016/j.taap.2009.11.019
17. Loftus N., Barnes A., Ashton S., Michopoulos F., Theodoridis G., Wilson I., Ji C., Kaplowitz N., Metabonomic investigation of liver profiles of nonpolar metabolites obtained from alcohol-dosed rats and mice using high mass accuracy MSn analysis. Journal of Proteome Research 2011 10 2 705 713 2-s2.0-79955371604 10.1021/pr100885w
18. Salek R. M., Maguire M. L., Bentley E., Rubtsov D. V., Hough T., Cheeseman M., Nunez D., Sweatman B. C., Haselden J. N., Cox R. D., Connor S. C., Griffin J. L., A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiological Genomics 2007 29 2 99 108 2-s2.0-34247842731 10.1152/physiolgenomics.00194.2006 (Pubitemid 46701991)
19. Nicholson J. K., Lindon J. C., Holmes E., 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999 29 11 1181 1189 2-s2.0-0032694577
20. Strauss V., Wiemer J., Leibold E., Kamp H., Walk T., Mellert W., Looser R., Prokoudine A., Fabian E., Krennrich G., Herold M., van Ravenzwaay B., Influence of strain and sex on the metabolic profile of rats in repeated dose toxicological studies. Toxicology Letters 2009 191 1 88 95 2-s2.0-70449133447 10.1016/j.toxlet.2009.08.004
21. Mellert W., Kapp M., Strauss V., Wiemer J., Kamp H., Walk T., Looser R., Prokoudine A., Fabian E., Krennrich G., Herold M., van Ravenzwaay B., Nutritional impact on the plasma metabolome of rats. Toxicology Letters 2011 207 2 173 181 10.1016/j.toxlet.2011.08.013
22. Fielden M. R., Eynon B. P., Natsoulis G., Jarnagin K., Banas D., Kolaja K. L., A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. Toxicologic Pathology 2005 33 6 675 683 2-s2.0-17844378132 10.1080/01926230500321213 (Pubitemid 43154594)
23. Nie A. Y., McMillian M., Parker J. B., Leone A., Bryant S., Yieh L., Bittner A., Nelson J., Carmen A., Wan J., Lord P. G., Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Molecular Carcinogenesis 2006 45 12 914 933 2-s2.0-33845462135 10.1002/mc.20205 (Pubitemid 44907382)
24. Fan X., Lobenhofer E. K., Chen M., Shi W., Huang J., Luo J., Zhang J., Walker S. J., Chu T. M., Li L., Wolfinger R., Bao W., Paules R. S., Bushel P. R., Li J., Shi T., Nikolskaya T., Nikolsky Y., Hong H., Deng Y., Cheng Y., Fang H., Shi L., Tong W., Consistency of predictive signature genes and classifiers generated using different microarray platforms. Pharmacogenomics Journal 2010 10 4 247 257 2-s2.0-77955127780 10.1038/tpj.2010.34
25. Kamp H., Fabian E., Groeters S., Herold M., Krennrich G., Looser R., Mattes W., Mellert W., Prokoudine A., Ruiz-Noppinger P., Strauss V., Walk T., Wiemer J., van Ravenzwaay B., Application of in vivo metabolomics to preclinical/toxicological studies: case study on phenytoin-induced systemic toxicity. Bioanalysis 2012 4 18 2291 2301 10.4155/bio.12.214
26. National Toxicology Program, Toxicology and carcinogenesis studies of 5,5-diphenylhydantoin (CAS No. 57-41-0) (phenytoin) in F344/N rats and B6C3F1 mice (feed studies). National Toxicology Program Technical Report Series 1993 404 1 303
27. Hayward R., Hydock D. S., Doxorubicin cardiotoxicity in the rat: an in vivo characterization. Journal of the American Association for Laboratory Animal Science 2007 46 4 20 32 2-s2.0-36048978125 (Pubitemid 351182139)
28. Sovcikova A., Tulinska J., Kubova J., Liskova A., Syrova D., Horakova K., Effect of cyclosporin A in Lewis rats in vivo and HeLa cells in vitro. Journal of Applied Toxicology 2002 22 3 153 160 2-s2.0-0036272673 10.1002/jat.842 (Pubitemid 34591513)
29. Ryffel B., Mihatsch M. J., Cyclosporine nephrotoxicity. Toxicologic Pathology 1986 14 1 73 82 2-s2.0-0022503753 (Pubitemid 16087016)
30. Josephine A., Nithya K., Amudha G., Veena C. K., Preetha S. P., Varalakshmi P., Role of sulphated polysaccharides from Sargassum Wightii in Cyclosporine A-induced oxidative liver injury in rats. BMC Pharmacology 2008 8 article 4 2-s2.0-42149184731 10.1186/1471-2210-8-4
31. Cushman D. W., Wang F. L., Fung W. C., Grover G. J., Harvey C. M., Scalese R. J., Mitch S. L., DeForrest J. M., Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). The British Journal of Clinical Pharmacology 1989 28 supplement 2 115S 131S 2-s2.0-0024448894 (Pubitemid 19270093)
32. Imai K., Yoshimura S., Ohtaki T., Hashimoto K., One month studies on the subacute toxicity of captopril in the rats. Journal of Toxicological Sciences 1981 6 supplement 2 189 214 2-s2.0-0019836209 (Pubitemid 12128622)
33. Roessner U., Wagner C., Kopka J., Trethewey R. N., Willmitzer L., Simultaneous analysis of metabolites in potato tuber by gas chromatography-mass spectrometry. Plant Journal 2000 23 1 131 142 2-s2.0-0034218717 10.1046/j.1365-313X.2000.00774.x (Pubitemid 30597788)
34. Yamada H., Yamahara A., Yasuda S., Abe M., Oguri K., Fukushima S., Ikeda-Wada S., Dansyl chloride derivatization of methamphetamine: a method with advantages for screening and analysis of methamphetamine in urine. Journal of Analytical Toxicology 2002 26 1 17 22 2-s2.0-0036141727 (Pubitemid 34074121)
35. van Ravenzwaay B., Herold M., Kamp H., Kapp M. D., Fabian E., Looser R., Krennrich G., Mellert W., Prokoudine A., Strauss V., Walk T., Wiemer J., Metabolomics: a tool for early detection of toxicological effects and an opportunity for biology based grouping of chemicals-from QSAR to QBAR. Mutation Research 2012 746 2 144 150 10.1016/j.mrgentox.2012.01.006
36. Looser R., Krotzky A. J., Trethewey R. N., Vaidyanathan S., Harrigan G. G., Goodacre R., Metabolite profiling with GC-MS and LC-MS-a key tool for contemporary biology. Metabolome Analyses: Strategies for Systems Biology 2005 New York, NY, USA Springer 103 118
37. Yamamura S., Hamaguchi T., Ohoyama K., Sugiura Y., Suzuki D., Kanehara S., Nakagawa M., Motomura E., Matsumoto T., Tanii H., Shiroyama T., Okada M., Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin. Epilepsy Research 2009 84 2-3 172 186 2-s2.0-64149105252 10.1016/j.eplepsyres.2009.01.015
38. Evered M. D., Robinson M. M., Increased or decreased thirst caused by inhibition of angiotensin-converting enzyme in the rat. Journal of Physiology 1984 348 573 588 2-s2.0-0021287360 (Pubitemid 14061871)
39. Evered M. D., Robinson M. M., The renin-angiotensin system in drinking and cardiovascular responses to isoprenaline in the rat. Journal of Physiology 1981 316 357 367 2-s2.0-0019732147 (Pubitemid 12253788)
40. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L., Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacological Reviews 2004 56 2 185 229 2-s2.0-2642566088 10.1124/pr.56.2.6 (Pubitemid 38720829)
41. Chitturi S., George J., Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Seminars in Liver Disease 2002 22 2 169 183 2-s2.0-0036251569 10.1055/s-2002-30102 (Pubitemid 34496470)
42. Bjornsson E., Hepatotoxicity associated with antiepileptic drugs. Acta Neurologica Scandinavica 2008 118 5 281 290
43. Russo M. W., Galanko J. A., Shrestha R., Fried M. W., Watkins P., Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transplantation 2004 10 8 1018 1023 2-s2.0-4544363071 10.1002/lt.20204 (Pubitemid 39232756)
44. McColl K. E. L., Moore M. R., Thompson G. G., Goldberg A., Induction of δ -aminolevulinic acid synthase in leukocytes of patients on phenytoin therapy: comparison with changes in rat hepatic tissue. The British Journal of Clinical Pharmacology 1980 9 4 327 331 2-s2.0-0018908110 (Pubitemid 10067052)
45. Jung J. W., Park J. S., Hwang J. W., Kang K. S., Lee Y. S., Song B. S., Lee G. J., Yeo C. D., Kang J. S., Lee W. S., Jeon K. S., Um C. H., Kim Y. S., Oh M. J., Youn J. P., Li P., Park J. E., Hwang S. Y., Gene expression analysis of peroxisome proliferators- and phenytoin-induced hepatotoxicity using cDNA microarray. Journal of Veterinary Medical Science 2004 66 11 1329 1333 2-s2.0-16644367550 10.1292/jvms.66.1329 (Pubitemid 41365447)
46. Huang Q., Jin X., Gaillard E. T., Knight B. L., Pack F. D., Stoltz J. H., Jayadev S., Blanchard K. T., Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutation Research 2004 549 1-2 147 167 2-s2.0-2142639373 10.1016/j.mrfmmm.2003.12.020 (Pubitemid 38553981)
47. Andrade R. J., Lucena M. I., Kaplowitz N., García-Munoz B., Borraz Y., Pachkoria K., García-Cortés M., Fernández M. C., Pelaez G., Rodrigo L., Durán J. A., Costa J., Planas R., Barriocanal A., Guarner C., Romero-Gomez M., Mu ņ oz-Yagüe T., Salmerón J., Hidalgo R., Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006 44 6 1581 1588 2-s2.0-33845666885 10.1002/hep.21424 (Pubitemid 44953663)
48. Helliwell T. R., Yeung J. H. K., Park B. K., Hepatic necrosis and glutathione depletion in captopril-treated mice. The British Journal of Experimental Pathology 1985 66 1 67 78 2-s2.0-0021960832 (Pubitemid 15168892)
49. Kurus M., Esrefoglu M., Sogutlu G., Atasever A., Melatonin prevents cyclosporine-induced hepatotoxicity in rats. Medical Principles and Practice 2009 18 5 407 410 2-s2.0-68249135331 10.1159/000226296
50. Kowdley K. V., Keeffe E. B., Hepatotoxicity of transplant immunosuppressive agents. Gastroenterology Clinics of North America 1995 24 4 991 1001 2-s2.0-0029555832 (Pubitemid 26107539)
51. Bennett W. M., Norman D. J., Action and toxicity of cyclosporine. Annual Review of Medicine 1986 37 215 224 2-s2.0-0022585813
52. Danesi R., Del Tacca M., Hematologic toxicity of immunosuppressive treatment. Transplantation Proceedings 2004 36 3 703 704 2-s2.0-2042540056 10.1016/j.transproceed.2004.03.016 (Pubitemid 38534366)
53. Rahman A., Treat J., Roh J. K., Potkul L. A., Alvord W. G., Forst D., Woolley P. V., A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. Journal of Clinical Oncology 1990 8 6 1093 1100 2-s2.0-0025369344 (Pubitemid 20200198)
54. Al-Shabanah O., Mansour M., El-Kashef H., Al-Bekairi A., Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochemistry and Molecular Biology International 1998 45 2 419 427 2-s2.0-0031874485 (Pubitemid 28331955)
55. Aviles A., Herrera J., Ramos E., Ambriz R., Aguirre J., Pizzuto J., Hepatic injury during doxorubicin therapy. Archives of Pathology and Laboratory Medicine 1984 108 11 912 913 2-s2.0-0021721319 (Pubitemid 15202908)
56. El-Sayyad H. I., Ismail M. F., Shalaby F. M., Abou-El-Magd R. F., Gaur R. L., Fernando A., Raj M. H. G., Ouhtit A., Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. International Journal of Biological Sciences 2009 5 5 466 473 2-s2.0-70249146563
57. Pillans P. I., Koopowitz A., Captopril-associated agranulocytosis. A report of 3 cases. South African Medical Journal 1991 79 7 399 400 2-s2.0-0025805097
58. Chen Y., Zheng X., Zou R., Wang J., Effects of cyclosporin-a on rat skeletal biomechanical properties. BMC Musculoskeletal Disorders 2011 12 article 240
59. Movsowitz C., Epstein S., Fallon M., Ismail F., Thomas S., Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988 123 5 2571 2577 2-s2.0-0023708625
60. Aroldi A., Tarantino A., Montagnino G., Cesana B., Cocucci C., Ponticelli C., Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation 1997 63 3 380 386 2-s2.0-0031016377 10.1097/00007890-199702150-00009 (Pubitemid 27086029)
61. Zannad F., Bray-Desboscs L., El Ghawi R., Donner M., Thibout E., Stoltz J. F., Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study. Journal of Hypertension 1993 11 5 559 564 2-s2.0-0027251495 10.1097/00004872-199305000-00012 (Pubitemid 23154347)
62. Gill J., Fonseca V., Dandona P., Jeremy J. Y., Lisinopril and nifedipine administration inhibits the ex vivo uptake of [45Ca2+] by platelets from hypertensive diabetic patients. The British Journal of Clinical Pharmacology 1992 33 2 161 165 2-s2.0-0026543383
63. Zordoky B. N. M., Anwar-Mohamed A., Aboutabl M. E., El-Kadi A. O. S., Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metabolism and Disposition 2011 39 8 1440 1450 2-s2.0-79960610491 10.1124/dmd.111.039123
64. Chang C. Y., Schiano T. D., Review article: drug hepatotoxicity. Alimentary Pharmacology and Therapeutics 2007 25 10 1135 1151 2-s2.0-34247519288 10.1111/j.1365-2036.2007.03307.x (Pubitemid 46650295)
65. Dodiya H., Jain M., Goswami S. S., Renal toxicity of lisinopril and rosuvastatin, alone and in combination, in wistar rats. International Journal of Toxicology 2011 30 5 518 527 10.1177/1091581811415293
66. Saltiel E., McGuire W., Doxorubicin (Adriamycin) cardiomyopathy. A critical review. Western Journal of Medicine 1983 139 3 332 341 2-s2.0-0020512823 (Pubitemid 13007385)
67. Robertson D. G., Watkins P. B., Reily M. D., Metabolomics in toxicology: preclinical and clinical applications. Toxicological Sciences 2011 120 supplement 1 S146 S170 2-s2.0-79952079197 10.1093/toxsci/kfq358
68. Robertson D. G., Reily M. D., Lindon J. C., Holmes E., Nicholson J. K., Heuvel J. P. V., Perdew G. H., Mattes W. B., Greenlee W. F., Metabonomic technology as a tool for rapid throughput in vivo toxicity screening. Cellular and Molecular Toxicology 2002 14 Amsterdam, The Netherlands Elsevier 583 610
69. Bundy J. G., Sidhu J. K., Rana F., Spurgeon D. J., Svendsen C., Wren J. F., Stürzenbaum S. R., Morgan A. J., Kille P., 'Systems toxicology' approach identifies coordinated metabolic responses to copper in a terrestrial non-model invertebrate, the earthworm Lumbricus rubellus. BMC Biology 2008 6 article 25 2-s2.0-45449111362 10.1186/1741-7007-6-25 (Pubitemid 351850957)
70. Takei M., Ando Y., Saitoh W., Tanimoto T., Kiyosawa N., Manabe S., Sanbuissho A., Okazaki O., Iwabuchi H., Yamoto T., Adam K. P., Weiel J. E., Ryals J. A., Milburn M. V., Guo L., Ethylene glycol monomethyl ether-induced toxicity is mediated through the inhibition of flavoprotein dehydrogenase enzyme family. Toxicological Sciences 2010 118 2 643 652 2-s2.0-78549250742 10.1093/toxsci/kfq211 kfq211
71. Ebbels T. M. D., Keun H. C., Beckonert O. P., Bollard M. E., Lindon J. C., Holmes E., Nicholson J. K., Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. Journal of Proteome Research 2007 6 11 4407 4422 2-s2.0-36348960223 10.1021/pr0703021 (Pubitemid 350158516)
72. Vassallo J. D., Hicks S. M., Daston G. P., Lehman-McKeeman L. D., Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity. Toxicological Sciences 2004 80 2 249 257 2-s2.0-4344599070 10.1093/toxsci/kfh162 (Pubitemid 39136379)
73. Schwerin M., Dorroch U., Beyer M., Swalve H., Metges C. C., Junghans P., Dietary protein modifies hepatic gene expression associated with oxidative stress responsiveness in growing pigs. The FASEB Journal 2002 16 10 1322 1324 2-s2.0-0036674242
74. Luyendyk J. P., Mattes W. B., Burgoon L. D., Zacharewski T. R., Maddox J. F., Cosma G. N., Ganey P. E., Roth R. A., Gene expression analysis points to hemostasis in livers of rats cotreated with lipopolysaccharide and ranitidine. Toxicological Sciences 2004 80 1 203 213 2-s2.0-3242777001 10.1093/toxsci/kfh146 (Pubitemid 38967411)